Advertisement
UK markets closed

  • NIKKEI 225

    37,552.16
    +113.55 (+0.30%)
     

  • HANG SENG

    16,828.93
    +317.24 (+1.92%)
     

  • CRUDE OIL

    83.38
    +1.48 (+1.81%)
     

  • GOLD FUTURES

    2,336.80
    -9.60 (-0.41%)
     

  • DOW

    38,508.00
    +268.02 (+0.70%)
     

  • Bitcoin GBP

    53,452.32
    +182.70 (+0.34%)
     

  • CMC Crypto 200

    1,432.81
    +18.05 (+1.28%)
     

  • NASDAQ Composite

    15,706.90
    +255.59 (+1.65%)
     

  • UK FTSE All Share

    4,378.75
    +16.15 (+0.37%)
     
Money:

What is the true cost of the UK state pension?

To get a sense of the true value of the state pension, you can look at how much you would need to save to match it yourself

BUZZ-Hikma: More price cuts on visibility issues

Reuters - UK Focus

** Hikma Pharmaceuticals (Frankfurt: A0HG69 - news) attempts bounce after steep losses since last week's half-year report, up as much as 3.9 pct, but these now almost erased (+0.4 pct)

** Morgan Stanley (Xetra: 885836 - news) cuts TP to 1350p from 1600p, Peel Hunt cuts TP to 1,390p from 2,150p

** MS sees short-term lack of clarity on market dynamics and a path to growth for Injectables and Generics, long term lack of visibility on pricing and competition

** Peel Hunt: with limited visibility on pipeline opportunities at Hikma, downgrades long-term outlook for generics business

** Stock down ~15% since drugmaker trimmed its sales forecasts last week

** Hikma down ~40 pct this yr (http://bit.ly/2ijIZDz)

** 6 of 13 brokerages rate stock "buy", 5 "hold", 2 "sell"; Median PT is 1,580p